Astra Zeneca diabetes drug shows heart protecting benefits

Astra Zeneca’s clinical study for diabetes drug Farxiga, meets a key goal, showing heart protecting benefits in a wide range of patients.
In a 17,000 patient trial, those on Farxiga achieved a significant reduction in hospitalisation for heart failure or CV death compared to those on placebo.
“We have demonstrated that Farxiga has improved heart rates in a wide range of patients in this trial.” Said Ludovic Helfgott, head of CV and metabolic disease at AstraZeneca. “We believe that this is something that should be recognised by the clinical community and regulators, and hope to have a new label by the end of next year.”